Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

被引：1
|
作者：
Shustov, Andrei R.
Coiffier, Bertrand
Horwitz, Steven M.
Sokol, Lubomir
Pro, Barbara
Nielsen, Tina
Wolfson, Julie
Balser, Barbara E.
Eisch, Robin
Popplewell, Leslie
Prince, Miles
Allen, Steven L.
Piekarz, Richard
Bates, Susan E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Chihara, Dai
    Oki, Yasuhiro
    Fayad, Luis
    Wesson, Emily
    Ruben, Charnelle
    Horowitz, Sandra B.
    Woolery, Joseph
    Feng, Lei
    Garg, Naveen
    Ahmed, Sairah
    Khouri, Issa F.
    Fanale, Michelle A.
    BLOOD, 2014, 124 (21)
  • [32] Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).
    Pinter-Brown, Lauren
    Horwitz, Steven M.
    Pro, Barbara
    Zinzani, Pier Luigi
    Gisselbrecht, Christian
    Cortelli, Barbara MacGregor
    Fruchtman, Steven
    O'Connor, Owen A.
    BLOOD, 2009, 114 (22) : 668 - 668
  • [33] Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat
    Savage, Kerry J.
    Horwitz, Steven M.
    Zinzani, Pier Luigi
    Van Hoof, Achiel
    Assouline, Sarit E.
    Bhat, Gajanan
    Choi, Mi Rim
    Allen, Lee F.
    Ben-Yehuda, Dina
    Jurczak, Wojciech
    Masszi, Tamas
    Shustov, Andrei R.
    BLOOD, 2014, 124 (21)
  • [34] Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival
    Shustov, A. R.
    Pro, B.
    Horwitz, S. M.
    Jacobsen, E. D.
    Boyd, A.
    Fruchtman, S. M.
    O'Connor, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
    O'Connor, O.
    Pro, B.
    Pinter-Brown, L.
    Popplewell, L.
    Bartlett, N.
    Lechowicz, M.
    Savage, K.
    Coiffier, B.
    Saunders, M.
    Horwitz, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
    Pro, Barbara
    Horwitz, Steven M.
    Prince, H. Miles
    Foss, Francine M.
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Morschhauser, Franck
    Wilhelm, Martin
    Iyer, Swaminathan Padmanabhan
    Shustov, Andrei R.
    Wolfson, Julie
    Balser, Barbara E.
    Coiffier, Bertrand
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 914 - 917
  • [37] Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens
    Goy, Andre
    Pro, Barbara
    Savage, Kerry Joanne
    Bartlett, Nancy L.
    Lechowicz, Mary Jo
    Jacobsen, Eric D.
    Young, Faith
    Crump, Michael
    Borghaei, Hossein
    Link, Brian
    Fruchtman, Steven M.
    O'Connor, Owen A.
    BLOOD, 2010, 116 (21) : 731 - 732
  • [38] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
    Brammer, Jonathan E.
    Zinzani, Pier Luigi
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Jacobsen, Eric D.
    Gritti, Giuseppe
    Litwak, Debra
    Cohan, David
    Katz, Danica J.
    Mehta-Shah, Neha
    Pro, Barbara
    Horwitz, Steven M.
    BLOOD, 2021, 138
  • [39] A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
    Cinzia Pellegrini
    Anna Dodero
    Annalisa Chiappella
    Federico Monaco
    Debora Degl’Innocenti
    Flavia Salvi
    Umberto Vitolo
    Lisa Argnani
    Paolo Corradini
    Pier Luigi Zinzani
    Journal of Hematology & Oncology, 9
  • [40] A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
    Pellegrini, Cinzia
    Dodero, Anna
    Chiappella, Annalisa
    Monaco, Federico
    Degl'Innocenti, Debora
    Salvi, Flavia
    Vitolo, Umberto
    Argnani, Lisa
    Corradini, Paolo
    Zinzani, Pier Luigi
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
12345